Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza a vaccine, MVA-NP+M1

Clinical Infectious Diseases

Volumn 52, Issue 1, 2011, Pages 1-7

  Berthoud, Tamara K ^a   Hamill, Matthew ^a   Lillie, Patrick J ^a   Hwenda, Lenias ^a   Collins, Katharine A ^a   Ewer, Katie J ^a   Milicic, Anita ^a   Poyntz, Hazel C ^a   Lambe, Teresa ^a   Fletcher, Helen A ^a   Hill, Adrian V S ^a   Gilbert, Sarah C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MATRIX PROTEIN 1; MATRIX PROTEIN 1 PLUS NUCLEOPROTEIN; MODIFIED VACCINIA VIRUS ANKARA; NUCLEOPROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR;

ADULT; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA A; INFLUENZA VACCINATION; INFLUENZA VIRUS A; MALAISE; NAUSEA; NONHUMAN; NUCLEOTIDE SEQUENCE; OPTIMAL DRUG DOSE; PANDEMIC; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RIGOR; VOLUNTEER; VOMITING;

ADOLESCENT; ADULT; CD8-POSITIVE T-LYMPHOCYTES; DRUG CARRIERS; FEMALE; GENETIC VECTORS; HUMANS; INFLUENZA VACCINES; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; INTERFERON-GAMMA; MALE; MIDDLE AGED; RNA-BINDING PROTEINS; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL CORE PROTEINS; VIRAL MATRIX PROTEINS; YOUNG ADULT;

EID: 79951645476     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq015     Document Type: Article

References (24)

1. Centers for Disease Control and Prevention (CDC). Interim withinseason estimate of the effectiveness of trivalent inactivated influenza vaccine-Marshfield, Wisconsin, 2007-08 influenza season. MMWR Morb Mortal Wkly Rep 2008;57:393-398.
2. de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A (H3N2) virus strain as the cause of an inadequate vaccineind (Pubitemid 30191232)
3. Galli G, Medini D, Borgogni E, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A 2009;106:3877-3882.
4. Nolan TM, Richmond PC, Skeljo MV, et al. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 2008;26:4160-4167.
5. Breathnach CC, Clark HJ, Clark RC, Olsen CW, Townsend HG, Lunn DP. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge. Vaccine 2006;24:1180-1190. (Pubitemid 43202264)
6. Donnelly JJ, Friedman A, Ulmer JB, Liu MA. Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Vaccine 1997;15:865-868. (Pubitemid 27287977)
7. Epstein SL, Kong WP, Misplon JA, et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005;23:5404-5410. (Pubitemid 41579312)
8. Laddy DJ, Yan J, Khan AS, et al. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol 2009;83:4624-4630.
9. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983;309:13-17. (Pubitemid 13062888)
10. McMichael AJ, Gotch FM, Dongworth DW, Clark A, Potter CW. Declining T-cell immunity to influenza, 1977-82. Lancet 1983;2:762-764. (Pubitemid 13003945)
11. Lee LY, Ha DLA, Simmons C, et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 2008;118:3478-3490.
12. He XS, Holmes TH, Zhang C, et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 2006;80:11756-11766. (Pubitemid 44788888)
13. Bejon P, Peshu N, Gilbert SC, et al. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya. Clin Infect Dis 2006;42:1102-1110.
14. Dorrell L, Yang H, Iversen AK, et al. Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine. AIDS 2005;19:1321-1323. (Pubitemid 41224902)
15. Sander CR, Pathan AA, Beveridge NE, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med 2009;179:724-733.
16. Vuola JM, Keating S, Webster DP, et al. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 2005;174:449-455. (Pubitemid 40007434)
17. Gilbert SC, Schneider J, Hannan CM, et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 2002;20:1039-1045. (Pubitemid 34135938)
18. McShane H, Pathan AA, Sander CR, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004;10:1240-1244. (Pubitemid 39540442)
19. Berthoud TK, Fletcher H, Porter D, Thompson F, Hill AV, Todryk SM. Comparing human T cell and NK cell responses in viral-based malaria vaccine trials. Vaccine 2009;28:21-27.
20. Webster DP, Dunachie S, McConkey S, et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2006;24:3026-3034.
21. Dunachie SJ, Walther M, Epstein JE, et al. A DNA primemodified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun 2006;74:5933-5942. (Pubitemid 44484581)
22. Priddy FH, Brown D, Kublin J, et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008;46:1769-1781. (Pubitemid 351706778)
23. Beveridge N, Price D, Casazza J, et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 2007;37:3089-3100. (Pubitemid 350131288)
24. Whelan KT, Pathan AA, Sander CR, et al. Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A. PLoS ONE 2009;4: e5934.